Lifecore Biomedical (LFCR) Projected to Post Quarterly Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is projected to post its Transition period results after the market closes on Thursday, April 2nd. Analysts expect Lifecore Biomedical to post earnings of ($0.27) per share and revenue of $25.9570 million for the quarter. Investors are encouraged to explore the company’s upcoming Transition period earning overview page for the latest details on the call scheduled for Monday, March 16, 2026 at 8:30 AM ET.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The firm had revenue of $35.75 million for the quarter, compared to analysts’ expectations of $35.31 million. Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Down 1.8%

NASDAQ:LFCR opened at $3.72 on Wednesday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. The firm’s 50-day moving average price is $6.68 and its 200-day moving average price is $7.21. The company has a market capitalization of $139.41 million, a PE ratio of -3.80 and a beta of 0.62. Lifecore Biomedical has a 1-year low of $3.63 and a 1-year high of $8.98.

Hedge Funds Weigh In On Lifecore Biomedical

Several large investors have recently modified their holdings of the stock. Quarry LP purchased a new stake in Lifecore Biomedical during the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets raised its holdings in Lifecore Biomedical by 92.7% in the third quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock worth $43,000 after buying an additional 2,786 shares during the last quarter. State of Wyoming purchased a new position in Lifecore Biomedical in the second quarter worth about $69,000. The Manufacturers Life Insurance Company bought a new position in shares of Lifecore Biomedical in the second quarter worth approximately $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after buying an additional 1,886 shares in the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LFCR shares. Weiss Ratings reissued a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd. Zacks Research raised shares of Lifecore Biomedical to a “hold” rating in a research note on Thursday, January 1st. Finally, Barrington Research reiterated an “outperform” rating and set a $5.50 target price on shares of Lifecore Biomedical in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.